ANIX: Margin operasi Anixa Biosciences Inc

Lambang korporat lan logo Anixa Biosciences, Inc. (ANIX)

Marginal income from core operations demonstrates profitability dynamics, where the parameter value reaches 0.00. The prospects for Anixa Biosciences, Inc. (ANIX) rely on the success of clinical trials for ovarian and breast cancer drugs. However, the lack of stable cash flow and early-stage development create significant risks. Furthermore, fierce patent battles in immunotherapy increase pressure from industry behemoths.

ANIX - Tingkat bathi operasi anixa.com ing rentang 04.07.2022 - 20.11.2026

ANIX (anixa.com): rincian analitis lan laporan miturut indikator

Analisis fundamental perusahaan:ANIX, Anixa Bio
Produk dadi Anixa Biosciences, Inc.

For Anixa Biosciences, Inc. (ANIX), which is currently in the clinical trial stage, the operating margin reflects the efficiency of R&D cost management. This metric is calculated as the ratio of operating income to revenue, measuring the business's ability to generate income before accounting for financial expenses. An analysis of the operating margin indicator reveals the company's high dependence on external financing. The negative trend confirms intensive capital burn. Investors should evaluate this figure as an indicator of the resource depletion rate.